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Abstract
Clear cell renal cell carcinoma (ccRCC) characterized by a tumor thrombus (TT) extending into the inferior vena cava (IVC)
generally indicates poor prognosis. Nevertheless, the risk for tumor recurrence after nephrectomy and thrombectomy
varies. An applicable and accurate prediction system to select ccRCC patients with TT of the IVC (ccRCC/TT) at high risk after
nephrectomy is urgently needed, but has not been established up to now. To our knowledge, a possible role of microRNAs
(miRs) for the development of ccRCC/TT or their impact as prognostic markers in ccRCC/TT has not been explored yet.
Therefore, we analyzed the expression of the previously described onco-miRs miR-200c, miR-210, miR-126, miR-221, let-7b,
miR-21, miR-143 and miR-141 in a study collective of 74 ccRCC patients. Using the expression profiles of these eight miRs we
developed classification systems that accurately differentiate ccRCC from non-cancerous renal tissue and ccRCC/TT from
tumors without TT. In the subgroup of 37 ccRCC/TT cases we found that miR-21, miR-126, and miR-221 predicted cancer
related death (CRD) accurately and independently from other clinico-pathological features. Furthermore, a combined risk
score based on the expression of miR-21, miR-126 and miR-221 was developed and showed high sensitivity and specificity
to predict cancer specific survival (CSS) in ccRCC/TT. Using the combined risk score we were able to classify ccRCC/TT
patients correctly into high and low risk cases. The risk stratification by the combined risk score (CRS) will benefit from
further cohort validation and might have potential for clinical application as a molecular prediction system to identify high-
risk ccRCC/TT patients.
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Introduction
ccRCC represents 2–3% of all solid neoplasms with a
worldwide annual increase in incidence of about 2% [1]. About
5-10% of ccRCCs extend into the renal vein or the IVC [2].
When this occurs without evidence of lymph node involvement or
distant metastasis, surgery offers the only potential cure [3],
whereas patients who present with metastatic disease have a poor
prognosis with a 5-year survival rate of less than 20% [4]. The 5-
year survival rates for patients with ccRCC/TT without evidence
of nodal or distant metastasis treated with nephrectomy and tumor
thrombectomy is 46% 265% [4,5,6,7]. Several studies have
evaluated the prognostic value of clinico-pathological features like
performance status, presence of metastasis, sarcomatoid features,
concomitant perinephritic fat invasion, tumor grade, level of TT
and histological subtype in ccRCC patients with venous involve-
ment [6,7,8].
Nevertheless, the impact of molecular markers in this setting has
been insufficiently studied up to now.
While a couple of biological markers have been tested and
validated in the attempt to improve risk stratification for ccRCC
patients [9], only limited data is available concerning ccRCC/TT
patients. Recently, Laird et al. reported on differential expression
of prognostic proteomic markers in primary tumor, venous TT
and metastatic ccRCC tissue. Ki67, p53, VEGF1 (vascular
endothelial growth factor 1), SLUG and SNAIL were significantly
higher expressed in metastases compared with primary tumor and
TT, but no difference between primary tumor and TT was seen
[10].
Establishment of adjuvant therapy concepts for ccRCC/TT
patients after radical surgical treatment have been hindered by
lacking reliability of prediction of outcome by both clinical and
molecular parameters to this date [9]. Because of that, the
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identification of novel markers is urgently needed if harbouring
personalized therapy and follow-up.
One current approach for molecular tumor characterization is
miR expression profiling [11]. MiRs are small noncoding RNA
strands that posttranscriptionally regulate gene expression and
appear to be modulators of urologic cancers [12]. Specific miR
profiles have been observed previously in ccRCC: we could show
recently that a combined risk score (CRS) of miR-21 and miR-126
accurately predicts survival in ccRCC cases [13].
Based on the existing literature we selected a panel of eight
miRs (miR 200c, miR-210, miR-126, miR-221, let-7b, miR-21,
miR-143, and miR-141) that were shown to be dysregulated in
ccRCC to analyse their expression in a study cohort containing
ccRCC/TT and ccRCC without TT (ccRCC/woTT) cases.
Table 1. Patient characteristics (n = 74).
Characteristics
Entire ccRCC
group (n =74)
ccRCC patients
without TT (n=37)
ccRCC patients
with TT (n =37)
Median Follow up 45.6 months 45.7 months 41.4 months
Median Age 66.8 years 68.0 years 65.6 years
Sex
Female 26 (35.1%) 17 (45.9%) 9 (24.3%)
Male 48 (64.9%) 20 (54.1%) 28 (75.7%)
Tumor Grade
G1 4 (5.4%) 4 (11%) 0
G2 52 (70.2) 30 (81%) 22 (59,5%)
G3 16 (21.6%) 3 (8%) 13 (35%)
G4 2 (2.7%) 0 2 (5.5%)
T stage
T1a 12 (16.2%) 12 (32.4%) 0
T1b 12 (16.2%) 12 (32.4%) 0
T2a/b 8 (10.8%) 8 (21.6%) 0
T3a 5 (6.8%) 5 (13.5%) 0
T3b 30 (40.5%) 0 30 (81.1%)
T3c 7 (9.6%) 0 7 (18.9%)
T4 0 0 0
N stage
N0 70 (94.6%) 37 (100%) 33 (89.2%)
N1 1 (1.4%) 0 1 (2.7%)
N2 3 (4.1%) 0 3 (8.1%)
Metastasis at time of surgery
Yes 18 (24.3%) 2 (5.4%) 16 (43.2%)
No 56 (75.7%) 35 (94.6%) 21 (56.8%)
Level of Tumor Thrombus (Mayo-classification)
no TT 37 (50%) 37 (100%) 0
Level I 5 (6.8%) 0 5 (13.5%)
Level II 10 (13.5%) 0 10 (27%)
Level III 15 (20.3%) 0 15 (40.5%)
Level IV 7 (9.5%) 0 7 (18.9%)
Infiltration of perinephritic tissue
yes 21 (28.4%) 5 (13.5%) 16 (43.2%)
no 53 (71.6%) 32 (86.5%) 21 (56.8%)
Clinical failure
Yes 28 (37.8%) 3 (8.1%) 25 (67.6%)
No 46 (62.2%) 34 (91.9%) 12 (32.4%)
Cancer related death
Yes 21 (28.4%) 1 (2.7%) 20 (54.1%)
No 53 (71.6%) 36 (97.3%) 17 (45.9%)
doi:10.1371/journal.pone.0109877.t001
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Here, we assessed expression of eight oncogenic miRs to
determine an expression profile which allowed us to distinguish
between ccRCC/TT patients and ccRCC patients not having
vascular invasion. To evaluate the potential role of miRs as
prognostic molecular markers in ccRCC/TT patients we finally
correlated the expression of selected miRs with clinico-patholog-
ical features and survival aiming towards a possible clinical use as
molecular markers.
Materials and Methods
Ethics statement
This study was approved by the local human research ethics
committee of the medical faculty of the University of Wuerzburg,
Germany (no. 136/08) and was conducted according to the
standards set by the declaration of Helsinki; all patients provided
written informed consent.
Table 2. Classification properties of miRNA for ccRCC/TT.
Learning set
Discrimination n miRNAs AUC 95% CI P-value Correct classification
RCC vs.
normal renal tissue
58 (42 tumor vs.
16 normal)
miR-21, miR-143, miR-200c,
miR-210, miR-126
1.00 100–100 ,0.0001 58/58 (100%)
RCC/TT vs.
RCC/woTT
37 (19 RCC/TT vs.
18 ccRCC/woTT)
let-7b, miR-21, miR-221 0.89 77.6-100 ,0.001 19/19 (100%)
Test set
Discrimination n miRNAs AUC 95% CI P-value Correct classification
RCC vs.
normal renal tissue
48 (tumor 32 vs.
normal 16)
miR-21, miR-143, miR-200c,
miR-210, miR-126
1.00 100–100 ,0.0001 48/48 (100%)
RCC/TT vs.
RCC/woTT
37 (18 RCC/TT vs.
19 ccRCC/woTT)
let-7b, miR-21, miR-221 0.82 68.15–96.18 0.002 17/18 (94%)
Abbreviations: RCC : renal cell carcinoma; TT : tumor thrombus; woTT : without tumor thrombus; AUC: area under receiver characteristic curve; normal: non-cancerous
renal tissue.
doi:10.1371/journal.pone.0109877.t002
Figure 1. Expression of miR-21, miR-126, miR-143, miR-221, let-7b, miR-210, miR-141, and miR-200c in ccRCC/TT. Relative expression
(DCt levels) of indicated miRs measured by qRT-PCR and normalized against RNU6B are shown as Box and Whisker-Plot. Expression of different miRs
in ccRCC/woTT (RCC, dark grey plots; n = 37) are compared with ccRCC/TT (black plots, n = 37). Expression in non-cancerous renal tissue (ctrl.; light
grey plots, n = 31) was shown as control. * P,0.05; ** P,0.01; *** P,0.001, ANOVA.
doi:10.1371/journal.pone.0109877.g001
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Patients and tissue sample
We collected paraffin embedded samples of 74 primary tumors
of ccRCC patients. After excluding other histological histological
subtypes (7 papillary, 3 sarcomatoid) we used samples of 37
primary tumors of ccRCC/TT patients who consecutively
underwent radical surgery at the Department of Urology and
Pediatric Urology of the Julius-Maximilians-University Medical
Center Wu¨rzburg between 1997–2010.
To evaluate the role of the selected miRs in development of
venous involvement, a comparison collective of consecutive
ccRCC cases without venous invasion (n= 37) was used. All
ccRCC samples were paraffin-embedded and areas with .90%
cancerous tissue were selected; likewise samples of histologically
benign renal tissue were reviewed by one experienced uropathol-
ogist (AR) and used non-cancerous renal tissue as controls. ccRCC
specimens were staged and graded according to the TNM
classification (2010 TNM classification of malignant tumors
(UICC, 7th edition) by a uropathologist (AR). The level of tumor
thrombus was classified according to the Mayo classification [14]
Clinical and pathological characteristics including follow up are
summarized in Table 1.
Preoperatively, all patients underwent routine blood test,
ultrasound, chest x-ray (or computed tomography (CT)), abdom-
inal CT and/or abdominal magnetic resonance imaging (MRI)
and/or bone scintigraphy. Long-term follow-up data were
collected during check-up visits, review of patient records and
additional telephone interviews with the urologists of the patients.
RNA Extraction and Reverse Transcription
Total RNA extraction from paraffin-embedded samples was
performed using the Recover all Total Nucleic Acid Isolation Kit
and the Total RNA Extraction Kit, respectively (Ambion and
miRNeasy Mini Kit, Qiagen). RNA concentration and A260/280
ratio were analysed with a Nano Drop ND-100 spectrometer
(NanoDrop Technologies, Wilmington) and RIN (RNA Integrity
Numbers) calculated with a Bioanalyzer. RNA samples showing
RIN,6.0 were excluded from further analysis. The resulting miR
was retained for quantitative Real Time PCR (qRT-PCR).
Specific cDNA was synthesized from total RNA with stem-loop
reverse transcription primers according to the TaqMan miRassay
protocol (PE Applied Biosystems).
qRT-PCR
MiR expression in tissue samples was quantified with Taq-
ManH miRassay kits and the BioRad OPTICON 2, following the
manufacturer’s instructions (BioRad). Primers for all miRs were
obtained from Applied Biosystems. Cycling conditions were
chosen according to manufacturer’s protocols. All reactions were
performed in triplicates and samples showing SD.0.5 were
excluded. Relative expression values of miRs were normalized to
small nuclear RNA (RNU6b) previously described as reference
gene. DCt for tumor samples and adjacent normal tissue of all
miRs were calculated by the comparative Ct method. All samples
characterized by expression levels of RNU6B.30 Ct were
excluded from further analysis.
Statistic, computional analysis and combined risk score
calculation
Thresholds for dichotomizing relative expressions of miRs were
determined by receiver operating characteristic (ROC) curves (R
package pROC [15]), based on CSS. Impact of clinic-pathological
parameters and various miRs on CSS was assessed by uni- and
multivariate COX regression analysis (R-package survival, [16]).
The best fitting COX model was selected by measuring the
relative goodness-of-fit with the Akaike information criterion
(AIC), which selected a combination of miR-21 miR-126 and
miR-221 as the best predictor. Calculation of a CRS of miR-21
miR-126 and miR-221 was implemented as proposed by Lossos
et al. [17]. In brief, a factor derived from the z-score, resulting
from the COX model, was determined for all three miRs. The
relative expression (DCt) of the different miRs were multiplied by
these factors using the formula (4.5926 DCt miR-21)+(23.8926
DCt miR-126)+(21.9386 DCt miR-221). A negative factor
indicates that higher expression correlates with longer survival,
whereas a positive factor correlates with shorter survival. A cut-off
for the risk score was again determined by ROC. Differences in
mean between miR-expression and clinical parameters were
analysed by Student’s t-test or ANOVA, respectively.
Results
Developing a classification model for discrimination of
ccRCC from normal kidney tissue based on miR
expression profiles
To analyze the expression of the selected oncomiRs (miR-200c,
miR-210, miR-126, miR-221, let-7b, miR-21, miR-143 and miR-
141) we used the entire collective (n = 106) including 37 cases of
ccRCC/TT patients and 37 cases without venous involvement
(ccRCC/woTT) as well as 32 cases of non-cancerous renal tissue.
We previously excluded all renal cell cancer (RCC) histo-
pathological subtypes others than ccRCC from our study
collective, as it was shown that different RCC subtypes are
characterized by distinct miR expression profiles [18,19]. Mean
expression of the selected eight miRs in the ccRCC samples were
calculated using normalized qRT-PCR data and compared to the
mean expression in normal kidney tissue (n = 32) (Fig. S1). We
observed significant upregulation of miR-21 and miR-210 in
ccRCC samples, while miR-141, miR-200c and miR-126 were
found to be downregulated in ccRCC cases. MiR-143, miR-221
and let-7b showed no significant differential expression (p.0.05).
Figure 2. Venn diagram showing relationships between miRs
that were differentially expressed in ccRCC/TT, ccRCC/woTT
and non-cancerous renal tissue (ctrl). Circles include up- or down-
regulated miRs for each pairwise comparison. Common miRs between
different comparisons are shown in the intersections.
doi:10.1371/journal.pone.0109877.g002
MicroRNAs as Prognostic Tools in Renal Cell Cancer with Tumor Thrombus
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e109877
To prove whether the expression profiles of the selected miRs
correctly discriminate ccRCC tissue from non-cancerous tissue, we
developed predictive rules using logistic regression. Therefore, we
randomly divided the study collective (n = 106) into a learning data
set of 58 samples containing 42 ccRCC samples and 16 samples of
normal kidney tissue and a test data set containing the remaining
48 samples (32 ccRCC cases and 16 samples from non-cancerous
kidney tissue). A combination of five miRs (miR-21, miR-143,
miR-200c, miR-210 and miR-126) was determined by the AIC to
accurately discriminate between normal kidney and ccRCC
samples (ccRCC/TT and ccRCC/woTT together) in the learning
data set. The area under the curve characteristics predicted 100%
sensitivity and specificity (AUC=1.00; p,0.001, Tab. 2). We then
applied the classification model to the test cohort containing the
remaining 32 tumor samples and 16 normal tissues. Using our
model for differentiation the accuracy to discriminate between
tumor and normal tissue was 100% in the testing cohort as
indicated in table 2. Though, we concluded that the combination
of these five miRs accurately differentiates ccRCC cases from
normal kidney tissue in our study collective.
Identification of miRs differentially expressed in ccRCC/TT
To identify miRs, which are specifically dysregulated in
ccRCC/TT cases, we compared the mean expression of the
selected miRs in these cases (n = 37) to non-cancerous renal tissue.
As shown in Fig. 1 we observed differential expression of all eight
miRs analyzed in ccRCC/TT when compared to non-cancerous
kidney tissue.
Next, we divided our study group into ccRCC/TT and
ccRCC/woTT cases (table 1). Comparing both groups we found
significant up-regulation of miR-21 and down-regulation of let-7b,
miR-126, miR-221, and miR-143 in ccRCC/TT cases (Fig. 1).
The mean expression of miR-141, miR-200c, and miR-210
showed no differential expression between both subgroups, but
was significantly regulated, if each group was compared separately
to non-cancerous kidney tissue. In contrast, miR-126 and miR-221
were down-regulated specifically in ccRCC/TT, but not in
ccRCC/woTT as compared to the controls. Fig. 2 summarizes
the differential expression of all miRs analyzed comparing
ccRCC/TT cases, ccRCC/woTT cases and normal renal kidney
using a Venn diagram. In addition to the specific down-regulation
Figure 3. MiR-21 and miR-126 expression is associated to positive LN metastases and survival. Relative expression (DCt levels) of miR-21
and miR-126 were analysed by qRT-PCR in ccRCC/TT samples and normalized using RNU6B. ccRCC/TT cases (n = 37) were divided into risk groups by
positive distant metastases (A) or cancer specific death throughout follow up (B). Significant changes in median expression for miR-21 and miR-126 in
between subgroups were calculated by unpaired student’s t-test and indicated in the Box and Whiskers plots.
doi:10.1371/journal.pone.0109877.g003
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of miR-126 and miR-221 in ccRCC/TT cases we found a very
robust progressive up-regulation of miR-21 in ccRCC/TT
suggesting that miR-21, miR-126 and miR-221 might be
specifically involved in the development of ccRCC/TT.
Developing a classification model for discrimination of
ccRCC/TT samples from ccRCC/woTT samples
Next, we evaluated whether the expression of these eight miRs
could accurately discriminate ccRCC/TT samples (n = 37) from
samples without invasion into the venous system (n= 37).
Therefore, we developed a new classification model by logistic
regression using a learning data set containing 37 ccRCC samples
(19 ccRCC/TT and 18 ccRCC/woTT cases), which was
randomly selected from the entire set of our study collective. By
linear regression analysis, a combination of miR-21, miR-221 and
let-7b was selected. All three together contributed essentially to the
predicting model. Using the expression data of these three miRs,
our model accurately determined ccRCC/TT samples with high
sensitivity and specificity (AUC=1.00; P,0.001, Tab. 2) in the
learning cohort. To validate the discriminative properties of this
classification model, we used an independent testing cohort
containing the remaining 37 primary ccRCC cases (18 ccRCC/
TT and 19 ccRCC/woTT). Using the defined parameters, this
model correctly classified 17 of 18 (94%) ccRCC/TT cases. To
further determine the properties of the model, we performed ROC
analysis. Using the determined logistic regression calculations the
AUC was 0.82 indicating a robust prediction of ccRCC/TT cases
by the combined expression profile of miR-21, miR-221 and let-7b
(see table 2).
Association of miR expression with ccRCC/TT
aggressiveness
To evaluate the possible impact of specific miRs as potential
outcome predictor within the ccRCC/TT collective, we associated
the expression of all eight miRs with positive distant metastasis at
time of surgery (16 of 37 ccRCC/TT cases; table 1) and to CSS
throughout follow up (20 of 37 ccRCC/TT cases; table 1) using
the ccRCC/TT study collective (n = 37). The median follow up of
the ccRCC/TT collective was 41.4 months with an actuarial 5-yr
cancer specific survival estimate of 43% (Fig. S2). As shown in
Fig. 3 and table 3, we observed significant up-regulation of miR-
21 and down-regulation of miR-126 in ccRCC cases with
metastasized disease at time of surgery or with CSS during follow
up, while all other miRs did not show significant association to
metastasis or survival (table 3).
Correlating miR signatures with cancer specific survival in
ccRCC/TT
ccRCC/TT, as expected, features markedly different biological
behavior. While around 43% of all cases from the ccRCC/TT
study group seem to be cured by aggressive surgery throughout 5-
yr follow-up time, around 57% of these cancers recurred early and
ultimately metastasized (Fig. S2). To determine which standard
clinico-pathological risk factors should be integrated into a
predictive algorithm to stratify patients at high risk for tumor
recurrence, we performed Cox regression analysis using several
risk factors including sex, age, tumor thrombus level, tumor grade,
tumor size, perinephric fat infiltration, positive LN metastasis or
positive distant metastasis at time of surgery. Only tumor grade,
positive LN metastasis, and positive distant metastasis were
univariately predicting CSS in the study group significantly and
were therefore chosen for further analysis. To determine which of
the eight miRs might be useful in predicting CSS thus being
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incorporated into a predictive algorithm consequently, we
calculated Kaplan Meier plots and Cox regression analysis for
all eight miRs using miR expression data (Fig. 4 and table 4).
Expression differences in miR-21 and miR-126 significantly
influenced CSS on Kaplan Meier estimates and univariate Cox
regression analysis, while miR-200c and miR-221 were moder-
ately significant to predict CSS in Kaplan Meier analysis.
Therefore, we decided to combine miR-21, miR-126, miR-200c
and miR-221 with the clinico-pathological factors tumor grade,
LN metastases and distant metastases to develop a prediction
model for CSS in ccRCC/TT patients. The potential of this
model to predict CSS was evaluated by Cox regression analysis
and Kaplan Meier estimates. To avoid overfitting of the model, we
performed stepwise regression analysis using AIC resulting in a
best model predicting CSS. This model used miR-21, miR-126
and miR-221 as multivariate significant factors indicating that
these factors were independent predictors of CSS in our study
collective (Fig. 5C). All clinico-pathological factors were not
chosen by the AIC based model suggesting they were not essential
for the predicting model. Using a previously described risk score
model [17], we determined and calculated a combined risk score
(CRS) for CSS based on the expression data of miR-21, miR-126
and miR-221 (used formula: (4.5926 DCt miR-21)+(23.8926
DCt miR-126)+(21.9386 DCt miR-221)). The calculated CRS
cut of level (high risk: CRS.18.7, low risk: CRS,18.7) divided
the ccRCC/TT study cohort of 37 cases in high risk (n = 22) and
low risk (n = 15) patients. Kaplan Meier plots and log rank tests
showed stratification by the model for predicting patient survival
(log rank p,0.001). Out of the 20 CRD cases, the risk score
correctly identified 18 cases as high risk patients (90% specificity)
and out of 16 cases with long term survival and without CRD
throughout follow-up 14 cases were correctly classified as low risk
patients (87% specificity). The predicted two and 5 year cancer
free survival in patients divided by the CRS were 49% and 18% in
the high risk group and 84% and 78% in the low risk group
respectively, indicating that the CRS robustly predicts survival and
CRD in ccRCC/TT patients. Additionally we observed that all 37
ccRCC samples without TT were correctly classified by the
determined CRS into 36 cases at low risk and one case at high risk
(data not shown). To test the performance of the predictive roles
for classification of RCC with TT we finally analyzed the
expression of miR-21, miR-126 and miR-221 in eight independent
RCC/TT cases and calculated the CRS for each cancer patient.
As shown in table 5 the CRS correctly classified 6 out of 7 high
Figure 4. Kaplan Meier survival analysis for CSS in ccRCC/TT (n=37) patients stratified by the dichotomized expression of miR-
200c, miR-21, mir-126 and miR-221. Risk scores (thresholds) for the miRs were determined by receiver operating characteristics (ROC) curves and
indicated in the plots. The ccRCC/TT study cohort (n = 37) was stratified by the CRS of miR-21, miR-126 and miR-221. p values resulting from log rank
tests are shown in the plots.
doi:10.1371/journal.pone.0109877.g004
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risk patients and one out of one patient at low risk for cancer
progression indicating that 7 out of 8 patients (87%) were correctly
classified by the CRS.
Discussion
Looking at ccRCC, only a minority of patients with advanced
tumors develop TT, resulting in limited numbers of available
ccRCC/TT study collectives. This might be one reason why up to
date, molecular and genetic changes causing the development of
vena cava extensions are poorly understood and applicable
prognostic marker systems in ccRCC/TT are still missing. Recent
studies have shown that miR expression profiling represents a
useful tool to elucidate the genetic and molecular basis of cancer
development and progression including ccRCC [20]. Comparison
of current miR expression studies revealed that the observed miR
profiles of ccRCC are highly reproducible among different patient
cohorts, suggesting a possible application of specific miRs as
diagnostic or prognostic biomarkers [13,18,21,22,23,24]. Based on
these studies, we selected a panel of eight different miRs, which
were previously described to be differentially expressed or to be
correlated with progression in ccRCC and determined their
expression in our ccRCC/TT study collective. Our aim was to
generate a basis for the development of new diagnostic and
prognostic tools in this important subgroup. As expected, we
confirmed differential expression of miR-21, miR-210, miR-141,
miR-200c and miR-126 in ccRCC. Using the expression data of
five miRs (miR-21, miR-143, miR-200c, miR-210 and miR-126),
we were able to separate ccRCC from normal kidney tissue with
an accuracy of 100%, indicating that our panel of miRs is related
to ccRCC development. Those results are in line with the
observed tumorigenic function of the selected miRs and with
recent studies successfully discriminating RCC from normal tissue
by the use of specific miR profiles [18,19,25].
Next, we presented results focusing on the establishment of a
discriminative miR profile to distinguish ccRCC/TT from
ccRCC/woTT. To date, no attempt has been made to classify
ccRCC/TT from ccRCC/woTT samples using miRs. We
observed that three miRs of our miR panel (miR-21, miR-126,
miR-221) were significantly regulated in ccRCC/TT. Moreover,
using the expression level of three miRs (miR-21, miR-221 and let-
7b) we successfully identified ccRCC/TT cases with an accuracy
of 94%. From these results, we concluded that among the eight
selected miRs miR-21, miR-126, miR-221 and let7b might be
critically involved in the development of ccRCC with TT. Several
studies already gave evidence that all four dysregulated miRs are
involved in biological processes controlling malignant transforma-
tion and progression of tumor cells by the identification or
prediction of various target mRNAs and pathways controlled by
these miRs [13,20,26,27,28,29]. Even if our study is limited by the
lack of functional and molecular analysis concerning the interac-
tion between miRs and potential target genes, the presented data
might provide the basis for further investigations. One common
hypothesis is that ccRCC/TT is an intermediate stage between
localized ccRCC and a metastasized ccRCC. This hypothesis is
supported by the observation that these miRs have been proposed
previously to be involved in formation of ccRCC metastasis
[13,20,30,31,32]. To understand how dysregulation of these miRs
might mediate venous invasion, aggressiveness or both in renal
cancer cells via posttranscriptional regulation of potential target
genes, it will be necessary to perform functional studies using
in vitro and in vivo models in the future.
An aggressive surgical approach is the only hope for curing
ccRCC patients with any level of TT. Many reports demonstrated
that a subgroup of patients with TT can achieve long term survival
after aggressive surgical treatment, suggesting that TT invasion in
the venous system is not necessarily associated with worse
prognosis and aggressiveness of the tumor at the time of surgery.
These results match our observation as our ccRCC/TT study
collective contains a patient subgroup characterized by low risk for
progressive disease. Nonetheless, patients with ccRCC/TT
Table 4. Univariate Cox regression of ccRCC/TT patients for indicated miRs and clinico-pathological factors.
CRD univariate
HR 95% CI p value (Likelihood ratio test)
let-7b 1.20 0.7003 2.055 p=0.507
miR-21 3.52 1.926 6.437 p,0.0001***
miR-143 0.97 0.667 1.419 p=0.885
miR-141 1.02 0.8064 1.286 p=0.880
miR-200c 0.95 0.7815 1.145 p=0.558
miR-210 1.14 0.9068 1.435 p=0.231
miR-126 0.50 0.2821 0.8686 p=0.012 *
miR-221 0.71 0.4449 1.135 p=0.139
LN metastases 3.21 1.491 6.929 p=0.010 *
distant metastases 3.47 1.438 8.367 p=0.005 *
perinephric fat invasion 1.44 0.6001 3.431 p=0.411
grading 2.06 1.129 3.743 p=0.026 *
tumor size 0.97 0.8431 1.115 p=0.660
tumor thrombus level 1.10 0.7099 1.689 p=0.680
age 1.04 0.9835 1.104 p=0.157
gender 0.97 0.3782 2.48 p=0.946
p,0.05 *; p,0.001**; p,0.0001***.
doi:10.1371/journal.pone.0109877.t004
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generally characterized as high risk patients having a relative poor
prognosis. We observed that a significant proportion of ccRCC/
TT patients developed early cancer recurrence while others could
be characterized by a long term disease free survival indicating the
importance of an additional risk stratification model to accurately
select patients who may benefit from early and intensified adjuvant
therapy. Therefore, one of the critical issues in treatment of
ccRCC/TT patients is the development of an accurate predicting
model system in these patients. The impact of a number of
prognostic nomograms typically including clinico-pathological
variables like TNM staging, tumor grade, performance status
and serum blood markers (hemoglobin, calcium, lactate dehydro-
genase, platelets, neutrophiles and c-reactive protein) have been
suggested for risk stratification in ccRCC/TT, but so far none of
these models achieve the status of an independent, reliable and
applicable predictor system in ccRCC/TT [9]. To improve the
accuracy of a predictive model system, it might be helpful to
establish molecular biomarkers in addition to standard factors
already applied. Systems using molecular biomarkers (e.g. miRs)
or a combination of molecular biomarkers with standard clinic-
pathological factors (e.g. IMP-3 and tumor staging), have been
shown to accurately predict progression and survival in ccRCC
tumors [33,34]. Nevertheless, up to now such predictive molecular
markers were not analyzed or identified in ccRCC/TT patients.
Here we show that a CRS calculated by the expression of three
miRs (miR-21, miR-126 and miR-221) has the potential to classify
ccRCC/TT patients that are at high or low risk to develop
aggressive disease. Surprisingly, even if we could show that some
standard clinic-pathological factors (lymph node metastasis, distant
metastasis and tumor grade) have predictive potential in our study
collective, the developed predictive model did not use any of these
factors implicating that the used CRS is able to classify patients at
high risk with pinpoint precision. The predictive power of the
determined risk score model is further supported by the
observation that 36 ccRCC/woTT are correctly classified as low
risk cases by the CRS. This observation is in conclusion with our
previous study demonstrating that the expression miR-21 and
miR-126 is associated with CSS in ccRCC/woTT [13]. Although
currently unable to validate the potential of the CRS in a large
independent control ccRCC/TT study group, the predictive
power of the CRS for ccRCC/TT might be further confirmed by
the correct risk stratification of seven out of eight independent
Figure 5. Kaplan Meier survival analysis and receiver operating characteristics (ROC) curve for CSS in ccRCC/TT patients (n=37)
stratified by the CRS for miR-21, miR-126 and miR-221. CRS were calculated as described in the material and methods part. A) ROC curve; the
cross indicates the calculated cutoff score for the CRS resulting in the highest sensitivity and specificity The selected cut off score is indicated in graph
B) The ccRCC/TT study cohort (n = 37) was stratified by the calculated risk score using Kaplan Meier analysis. Kaplan Meier curves with log rank test
and risk stratification by CRS are shown. C) Uni- and multivariate Cox regression analysis for cancer related death in the ccRCC/TT collective
determined by relative goodness of fit with AIC including selected miRs and clinico-pathological factors as variable.
doi:10.1371/journal.pone.0109877.g005
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RCC/TT patients. The potential involvement of miR-21, miR-
126 and miR-221 in regulation of progression and aggressiveness
is also supported by recent studies. Thus, miR-221 down-
regulation was recently described as a prognostic marker in high
risk prostate cancer controlling the interferon signal pathway in
cancer cells and was found to be under-expressed in metastatic
ccRCC cases [28,30]. Dysregulation of miR-21 and miR-126 was
demonstrated in various cancer types including ccRCC showing
involvement of these miRs in important tumorigenic pathways
controlling proliferation, angiogenesis, differentiation and migra-
tion [21,26,31,35,36]. Moreover, we have recently shown that a
CRS of miR-21 and miR-126 is correlated with survival in ccRCC
[13]. Thus, the determined CRS based on the expression of the
three onco-miRs demonstrates a possible molecular model to
classify ccRCC/TT samples into risk groups for the first time.
Since currently no other predictive molecular marker system exists
which can identify ccRCC/TT cases by their risk for its outcome,
the generation of a robust and specific prediction model is urgently
needed. Although the developed CRS model provides high
significance and accuracy for predicting CSS in ccRCC/TT, the
power of our conclusions is limited by low number of cases, by the
lack of confirmation in a large independent validation cohort and
by the retrospective nature of the current study. Therefore, it will
be necessary to test the effectiveness and reliability in further
studies with enlarged validation cohorts to confirm the potential of
the determined risk score as a predictive biomarker and possible
molecular assay in clinical setting.
In summary, we successfully characterized ccRCC/TT by a
distinct miR profile generated by the expression of eight selected
oncogenic miRs. The used miR profile is able to accurately classify
ccRCC/TT cases. Differential expression of miR-21, miR-221
and let-7b precisely separated ccRCC/TT cases from ccRCC/
woTT indicating their possible function in the development of
ccRCC/TT. Moreover, a CRS calculated by the expression of
three onco-miRs, miR-21, miR-126, and miR-221 was generated,
which accurately predicts CSS in the ccRCC/TT collective and in
a small independent RCC/TT patient group. Nevertheless, the
power of our conclusion may be limited by the relatively small
number of ccRCC/TT cases and has to be validated in large
ccRCC/TT cohorts. After further evaluation of the reliability and
effectiveness of the developed prediction model, we suppose this
prognostic molecular marker system will be able to carefully select
RCC/TT patients to whom an adjuvant systemic therapy may be
advisable.
Supporting Information
Figure S1 Expression of miR-21, miR-210, miR-200c,
miR-141, miR-126, let-7b miR-221, and miR-143 in
ccRCC. Relative expression (DCt levels) of indicated miRs were
measured by qRT-PCR and normalized against RNU6B and are
shown as Box and Whisker-Plot. Expression of different miRs in
ccRCC (RCC, dark grey plots; n = 74) are compared with non-
cancerous renal tissue (ctrl.; light grey plots, n = 32). * P,0.05; **
P,0.01; *** P,0.001, Student’s t-test.
(TIF)
Figure S2 Kaplan Meier survival analysis for CSS of
renal cell cancer with tumor thrombus patients (n=37)
median follow up of the study group was 41.4 months.
The 5-yr CSS estimate was 43%. CRD: cancer related death; FU:
follow up.
(TIF)
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